ArticleBMC ophthalmology2025
Neovascular glaucoma: comprehensive evaluation of etiology, treatment modalities, and visual prognosis.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Outcomes of the Paul Glaucoma Implant in an Ambispective Multicenter Study: 12-Month Follow-Up.Biomedicines · 2026Article
- Neovascular glaucoma: pathophysiology, diagnosis, and contemporary management.Frontiers in medicine · 2026Review
- Systemic Inflammatory and Microcirculatory Determinants of Long-Term Outcomes in Neovascular Glaucoma: A Multicenter Cohort Study.Romanian journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to determine the demographic characteristics of patients with neovascular glaucoma (NVG), identify the factors involved in its etiology, and evaluate the effects of various treatment methods on intraocular pressure (IOP).
methodsThis study included 29 eyes of 24 patients diagnosed with neovascular glaucoma who were treated and followed at a single tertiary eye care center. Patient demographics, medical history, and treatment protocols were recorded, including anti-VEGF injections, panretinal photocoagulation (PRP), and surgical interventions. IOP measurements and best-corrected visual acuity (BCVA) were monitored throughout the follow-up period.
resultsOf the patients included in the study, 6 were women and 18 were men, with an average follow-up period of 44.2 ± 34.8 months. The mean age of patients was 67.9 ± 11.4 years, with NVG being caused by diabetic retinopathy (11 eyes), central retinal vein occlusion (6 eyes), ocular ischemic syndrome (6 eyes), and other factors. Pre-treatment IOP was 36.7 ± 7.9 mmHg, which decreased to 18.03 ± 3.19 mmHg post-treatment. Surgical interventions were required in 9 eyes, and significant postoperative IOP reduction was observed. (p˂0.05) Bevacizumab was the most commonly used anti-VEGF agent, with visual acuity outcomes varying among patients, though no statistically significant improvement in BCVA was noted.
conclusionNVG is a severe condition that requires prompt treatment to prevent permanent vision loss. Anti-VEGF therapy and PRP are essential in controlling neovascularization and reducing IOP, while surgical intervention is often necessary in advanced cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.